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ABSTRACT.
Purpose: To describe nepafenac use in the Netherlands and Denmark with
reference to its approved indications. For context, we also describe the use of
ketorolac and diclofenac.
Methods: We identified users in the PHARMO Database Network (the
Netherlands, 2008–2013) and the Danish national health registers (Denmark,
1994–2014). We described prevalence of cataract surgery and duration of use in
patients with cataract surgery with and without diabetes.
Results: In the Netherlands, 9530 nepafenac users (mean age, 71 years; 60%
women) contributed 12 691 therapy episodes, of which 21% had a recently
recorded cataract surgery. Of 2266 episodes in adult non-diabetic patients with
cataract surgery, 60% had one bottle dispensed (treatment duration ≤21 days).
Of 441 episodes in adult diabetic patients with cataract surgery, 90% had up to
two bottles dispensed (≤60 days).Denmark had 60 403 nepafenac users (mean
age, 72 years; 58% women) and 73 648 episodes (41% had recorded cataract
surgery). Of 26 649 nepafenac episodes in adult non-diabetic patients with
cataract surgery, 92% had one bottle dispensed. Of 3801 episodes in adult
diabetic patients with cataract surgery, 99.8% had up to two bottles
dispensed.Use patterns of nepafenac, ketorolac and diclofenac were roughly
similar in the Netherlands, but not in Denmark.
Conclusion: Less than half of therapy episodes were related to cataract surgery;
around 90% of episodes with surgery were within the approved duration. Under-
recording of ophthalmic conditions and procedures was a challenge in this study.
Key words: cataract – cataract surgery – diclofenac – ketorolac – nepafenac – oﬀ-label – ophthalmic
NSAIDs
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Introduction
Nepafenac is an ophthalmic non-ster-
oidal anti-inﬂammatory drug (NSAID)
sold under the trade name Nevanac.
Nevanac 1 mg/ml has been available in
Europe since 2007 for the prevention
and treatment of postoperative pain
and inﬂammation after cataract
surgery, in the ﬁrst 2 weeks after
surgery in adults. Treatment can be
extended to the ﬁrst 3 weeks of the
postoperative period as directed by the
clinician. In 2011, the European Com-
mission approved a new indication for
Nevanac 1 mg/ml: reduction in the risk
of postoperative macular oedema asso-
ciated with cataract surgery in patients
with diabetes, for use up to 60 days
after surgery. Following this, an appli-
cation for a line extension was submit-
ted to register nepafenac 3 mg/ml with
the indication ‘prevention and treat-
ment of postoperative pain and inﬂam-
mation associated with cataract
surgery’, which was granted in 2013.
In July 2016 (after the end of the study
period), a new indication was approved
for nepafenac 3 mg/ml: reduction in
the risk of postoperative macular
oedema associated with cataract sur-
gery in patients with diabetes.
Other ophthalmic NSAIDs are
approved for broader indications; for
example, ophthalmic ketorolac is
approved for prevention and relief of
eye inﬂammation after eye surgery in
adults in the UK (Allergan Pharma-
ceuticals Ireland 2014), and diclofenac
is approved for mydriasis during sur-
gery, to control pain and inﬂammation
after eye surgery or injury and to
control symptoms of seasonal allergic
conjunctivitis (Excelvision S.A.S.
2015).
As part of the risk management plan
for nepafenac agreed between the
European Medicines Agency and
Alcon Inc., we performed a
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postapproval safety study (PASS). We
evaluated the dispensing of nepafenac
with regard to the approved indica-
tions, focusing on age, use related to
cataract surgery and duration of use in
patients with cataract surgery with and
without diabetes. To provide context to
the ﬁndings, we compared the dispens-
ing of nepafenac with that of other
ophthalmic NSAIDs (ketorolac and
diclofenac).
Materials and Methods
This was a descriptive observational
drug utilization study of users of
nepafenac, ketorolac and diclofenac.
The study was conducted in the
PHARMO Database Network
(PHARMO) of the PHARMO Insti-
tute for Drug Outcomes Research in
the Netherlands and in the network of
national health registers in Denmark.
The study period was 01 September
2008 through 31 October 2013 in the
Netherlands and 01 January 1994
through 31 December 2014 in Den-
mark.
Data sources
PHARMO Database Network is a
population-based network of electronic
healthcare databases that combines
data from diﬀerent primary and sec-
ondary healthcare settings in the
Netherlands. These diﬀerent data
sources, including data from general
practices, inpatient and outpatient
pharmacies, clinical laboratories, hos-
pitals and more, are linked on a patient
level through a validated algorithm.
The longitudinal nature enables a fol-
low-up of more than 4 million (25%)
residents of a well-deﬁned population
in the Netherlands for an average of
10 years (Herings 1993).
The entire Danish population is
provided free tax-supported medical
care by the National Health Service
(Thygesen & Ersboll 2014). For admin-
istration and maintenance of this
healthcare system, numerous adminis-
trative and health registries have been
established. The three main data
sources for this study were the Danish
Prescription Registry, the Danish
National Patient Registry and the Cen-
tral Person Registry. The Danish Pre-
scription Registry contains data on all
prescription drugs dispensed to Danish
residents since 1995 (Kildemoes et al.
2011). The data include the type of
drug, date of dispensing and quantity
dispensed. Drugs are categorized
according to the Anatomical Thera-
peutic Chemical Index (Kildemoes
et al. 2011). The Danish National
Patient Register contains nationwide
data on all non-psychiatric hospital
admissions since 1977 and all outpa-
tient specialist contacts in hospital
setting since 1995 (Schmidt et al.
2015). Discharge/contact diagnoses
are coded using ICD-8 (1977–1993)
and ICD-10 (1994-present). The Cen-
tral Person Registry contains records
of deaths and migrations, which
allowed us to follow patients appropri-
ately (Schmidt et al. 2014). Data
sources were linked by the civil registry
number, a unique identiﬁer assigned to
all Danish residents since 1968 (Sch-
midt et al. 2014).
Study population
Patients became eligible for cohort
entry after 6 months of enrolment in
the data source. In Denmark, the
cohort comprised only new users:
patients entered the cohort with the
ﬁrst dispensing for the drug after
6 months free of dispensing for that
drug. In the Netherlands, patients
entered the cohort regardless of previ-
ous ophthalmic NSAID use. Follow-up
continued until the earliest of disenrol-
ment from the database, emigration,
death or end of the study period.
Multiple episodes of use of one or
more of the study drugs by individual
patients were included if they occurred
during follow-up.
Analysis
Drug use was ascertained from com-
munity pharmacy dispensing records
(Kildemoes et al. 2011). Therapy epi-
sodes were created by linking together
consecutive dispensings without treat-
ment gaps.
The indication is not recorded in
either data source but was derived from
diagnoses and procedures dated within
30 days before and 30 days after the
prescription dispensing date.
In the Netherlands, cataract surg-
eries were identiﬁed from procedures in
hospital discharge records in the
Hospitalisation Database in
PHARMO. This database captures
only admissions longer than 24 hrs
and admissions less than 24 hrs for
which a bed is required. As the oph-
thalmic procedures in this study were
performed mainly during outpatient
visits, the number of ophthalmic pro-
cedures is likely to be underestimated.
In Denmark, cataract surgeries were
identiﬁed from diagnostic and proce-
dure codes in hospital discharge
records (Schmidt et al. 2015) and from
the DUSAS registry, which records
procedures conducted by primary care
specialists. During the conduct of this
study, evidence of underrecording of
cataract surgery in the Danish reg-
istries appeared (Solborg Bjerrum et al.
2013, 2015).
Sensitivity analyses implemented in
both populations to address under-
recording of cataract surgery included
expanding the list of ophthalmic con-
ditions for which nepafenac is not
approved but for which physicians
may have been providing prescriptions.
Additionally, in PHARMO, we identi-
ﬁed the presence of correspondence
between general practitioners and oph-
thalmologists and expanded the inter-
val in which the indication was sought
to within 60 days before or after the
start of the therapy episode, or
6 months before. In Denmark, we
conducted subgroup analyses in
patients whose surgeries were likely to
be captured better in our data sources:
the sicker patients (Charlson comor-
bidity score ≥ 3) and the elderly
(age ≥ 80 years) (Solborg Bjerrum
et al. 2013, 2015).
Because we did not have informa-
tion on when patients stopped therapy,
but we did have information on the
number of dispensed bottles, we used
the number of dispensed bottles as a
proxy for duration of therapy for
nepafenac. We assumed that one bottle
of nepafenac (3 ml or 5 ml) repre-
sented treatment for up to 21 days
and two bottles represented treatment
for up to 60 days. Because the macular
oedema indication for nepafenac was
approved in late 2011, we looked at the
number of bottles used in two periods,
before June 2011 and after January
2012 (before approval of the second
indication, the approved indication
would require no more than one bottle
per therapy episode). We also present
information on duration of use in days
based on physician instructions (spar-
sely available) or (more frequently) the
maximum possible duration based on
510
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the approved dosing and the size of the
bottle (e.g. one 3-ml bottle of nepafe-
nac 3 mg/ml would last up to 60 days
at 1 drop/day). As we do not have
direct evidence that all dispensed med-
ication was used, this is likely an
overestimation of the treatment dura-
tion. Furthermore, the package leaﬂet
recommends discarding any remaining
content 4 weeks after opening the
bottle to minimize the risk of infection
(Alcon 2015).
Patient baseline characteristics and
medication use were determined in the
6 months prior to cohort entry for
nepafenac, ketorolac and diclofenac.
We also determined drug use over time
and concomitant use of other oph-
thalmic medications and selected sys-
temic medications. Drug use in the
Netherlands in 2013, quantiﬁed from 1
January to 31 October, was extrapo-
lated to 31 December for graphic
display.
The study and its protocol were
registered in the EU PAS Register on
27 November 2013, prior to the start
of data collection (http://www.ence
pp.eu/encepp/viewResource.htm?id=
13363).
Results
The Netherlands
Participants and drug dispensing
The study cohort comprised 9530
nepafenac users with 1.3 therapy epi-
sodes per person, 5351 ketorolac users
(1.4 episodes per person) and 4536
diclofenac users (1.3 episodes per per-
son). While the number of episodes was
similar for the three drugs in 2009, only
dispensing of nepafenac continued
increasing thereafter, with a slight
decrease in the last year of the study
period (Fig. 1). Of nepafenac users,
60% were women, 17% were diabetic
and 39% were using antithrombotic
agents (Table 1). The demographics,
health characteristics and dispensing of
ophthalmic and systemic drugs to users
Fig. 1. Episodes of Use of Nepafenac, Ketorolac and Diclofenac, the Netherlands. The ﬁgure
starts in 2009, which is the ﬁrst year with complete data. Dashed lines correspond to extrapolated
data for 2013 (observed data up to 31 October 2013).
Table 1. Patient characteristics at baseline, the Netherlands (2008–2013) and Denmark (1994–2014)
Variables
the Netherlands Denmark
Users of
nepafenac
(n = 9530)
n (%)
Users of
ketorolac
(n = 5351)
n (%)
Users of
diclofenac
(n = 4536)
n (%)
Users of
nepafenac
(n = 60 403)
n (%)
Users of
ketorolac
(n = 54 185)
n (%)
Users of
diclofenac
(n = 131 440)
n (%)
Age (years)
≤ 18 27 (0.3) 24 (0.4) 35 (1) 197 (0.3) 2038 (4) 6231 (5)
> 18 9503 (>99) 5327 (>99) 4501 (99) 60 206 (>99) 52 147 (97) 125 209 (95)
Mean (SD) 71 (11) 70 (13) 70 (14) 72 (12) 63 (20) 52 (21)
Female sex 5758 (60) 3227 (60) 2714 (60) 35 075 (58) 33 017 (61) 62 880 (48)
Systemic conditions
Diabetes mellitus* 1608 (17) 786 (15) 769 (17) 7027 (12) 3668 (7) 6212 (5)
Autoimmune disorders 104 (1) 60 (1) 50 (1) 303 (0.5) 183 (0.3) 307 (0.2)
Bleeding disorders 4 (<0.1) 1 (<0.1) 3 (0.1) 6 (<0.1) 6 (<0.1) 26 (<0.1)
Use of systemic medications
Antithrombotic agents 3738 (39) 1838 (34) 1638 (36) 13 916 (23) 7576 (14) 10 874 (8)
NSAIDs 1463 (15) 811 (15) 690 (15) 3947 (7) 4205 (8) 10 613 (8)
Steroids 814 (9) 393 (7) 304 (7) 2104 (4) 2106 (4) 3428 (3)
Charlson comorbidity score†
0 – – – 27 823 (46) 32 960 (61) 94 399 (72)
1–2 – – – 20 639 (34) 14 990 (28) 27 041 (21)
≥3 – – – 11 941 (20) 6235 (12) 10 000 (8)
NSAIDs = non-steroidal anti-inﬂammatory drugs; SD = standard deviation.
Medical conditions and drug use were ascertained in the 6 months prior to the index date.
* Based on dispensing records and/or diagnostic codes.
† The comorbidity analysis was included in Denmark after information regarding underrecording of cataract surgery performed in private hospitals
became available, and that older and sicker patients were more likely to have surgery in public hospitals, where cataract surgery is recorded more
reliably.
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of ketorolac and diclofenac were very
similar to those of nepafenac users
(Table 1).
Age
The average age of users of nepafenac
was 71 years at cohort entry. Of 12 691
nepafenac therapy episodes, 34 epi-
sodes (0.3%) were in persons aged
18 years or younger (Table 2). Simi-
larly, few episodes of ketorolac or
diclofenac dispensing were in children,
less than 1% for both ketorolac and
diclofenac.
Cataract surgery, cataract diagnosis, other
diagnoses
Of the 12 657 nepafenac episodes in
adults, 21% were within the 30 days
before and 30 days after cataract sur-
gery (24% within 60 days before and
60 days after the start of the therapy
episode and 12% in the 6 months
before the start of the episode)
(Table 2). Of the 79% without a record
of cataract surgery within the 30 days
before and 30 days after the start of the
therapy episode, 19% had a cataract
diagnosis in the same window.
Furthermore, 57% had an ophthalmic
procedure, ophthalmic condition or
ophthalmic correspondence in that
window. This was 50% for ketorolac
and 54% for diclofenac. Less than 1%
of the episodes in adults were
associated with each of refractive
procedures or ophthalmic conditions
other than cataracts. Percentages for
ketorolac and diclofenac were similar
(Table 2).
Number of bottles
In all but two nepafenac-use episodes,
the formulation used was 1 mg/ml,
sold in 5-ml bottles (Table 3). Nepafe-
nac therapy episodes involved one
bottle in 60% of the 2266 episodes in
adult patients with surgery and with-
out diabetes (proxy for the authorized
duration ≤ 21 days). Up to two bottles
were involved in 90% of the 441
episodes in adult patients with cataract
surgery and diabetes (two bottles were
a proxy for the authorized dura-
tion ≤ 60 days). Of 2013 therapy epi-
sodes with recorded cataract surgery in
adults starting between 01 September
2008 and 30 June 2011 (when only the
ﬁrst indication had been approved),
56% were for one bottle (Table S1).
Later, between 01 January 2012 and 31
October 2013 (when both indications
had been approved), 78% of 626 ther-
apy episodes in adults with recorded
cataract surgery were for the autho-
rized duration (one bottle in patients
with cataract surgery and no diabetes,
or up to two bottles in patients with
recorded cataract surgery and dia-
betes). With some variation, the distri-
butions of duration of use of ketorolac
and diclofenac were not very diﬀerent
from that of nepafenac (Table 3).
Ketorolac use in patients not undergo-
ing cataract surgery tended to be
longer than use of nepafenac or diclo-
fenac.
Concomitant medications
The frequency of use of concomitant
medications varied somewhat across
drugs, with concomitant ophthalmic
steroid use around 80% or higher in
patients with recorded cataract
surgery and lower in patients not
undergoing cataract surgery (Table 4).
In patients with ketorolac
Table 2. Medical conditions associated with therapy episodes of Ophthalmic nepafenac, ketorolac and diclofenac in adults, the Netherlands (2008–
2013) and Denmark (1994–2014)
Variables
the Netherlands Denmark
Nepafenac
episodes
(N = 12 691)
n (%)
Ketorolac
episodes
(N = 7540)
n (%)
Diclofenac
episodes
(N = 5950)
n (%)
Nepafenac
episodes
(N = 73 648)
n (%)
Ketorolac
episodes
(N = 102 334)
n (%)
Diclofenac
episodes
(N = 184 361)
n (%)
Patients aged > 18 years
Number of episodes 12 657 (>99) 7508 (>99) 5915 (>99) 73 411 (>99) 99 484 (97) 177 754 (96)
Ophthalmic procedures
Cataract surgery 2707 (21) 1437 (19) 916 (15) 30 450 (41) 10 951 (11) 17 885 (10)
Refractive procedures 1 (<0.1) 1 (<0.1) 0 (0) 5 (<0.1) 180 (0.2) 2306 (1)
Ophthalmic conditions
Cataract 4503 (36) 2606 (35) 2023 (34) – – –
Dry eyes/Sj€ogren syndrome 8 (0.1) 5 (0.1) 8 (0.1) 24 (<0.1) 76 (0.1) 106 (0.1)
Uveitis/iritis 13 (0.1) 4 (0.1) 5 (0.1) 98 (0.1) 106 (0.1) 457 (0.3)
Ophthalmic manifestations of allergy 3 (<0.1) 4 (0.1) 14 (0.2) 0 (0) 0 (0) 0 (0)
Ocular pain 7 (0.1) 4 (0.1) 8 (0.1) – – –
Macular oedema 6 (<0.1) 2 (<0.1) 1 (<0.1) 14 (<0.1) 33 (<0.1) 46 (<0.1)
Vitreous-related disorders 17 (0.1) 0 (0) 5 (0.1) 75 (0.1) 99 (0.1) 258 (0.1)
Infectious conjunctivitis 21 (0.2) 10 (0.1) 26 (0.4) – – –
Blepharitis/stye/chalazion 21 (0.2) 8 (0.1) 5 (0.1) – – –
Eye infection/inﬂammation 11 (0.1) 8 (0.1) 15 (0.3) – – –
Ophthalmic correspondence 4763 (38) 2227 (30) 2172 (37) – – –
Episodes in patients aged > 18 years
with Charlson score ≥ 3
– – – 14 997 12 570 16 888
Cataract surgery – – – 6649 (44) 2233 (18) 3292 (20)
Episodes in patients aged ≥ 80 years – – – 19 243 22 723 23 467
Cataract surgery – – – 8552 (44) 3277 (14) 5186 (22)
Data were ascertained within the 30 days before and 30 days after the start date of the therapy episode. In this table, results from the Netherlands
only or from Denmark only represent database-speciﬁc sensitivity analyses.
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prescriptions, concomitant dispensing
of ophthalmic NSAIDs was high,
around 65%.
Denmark
Participants and drug dispensing
The study cohort comprised 60 403
users of nepafenac (1.2 episodes per
person), 54 185 users of ketorolac (1.9
episodes per person) and 131 440 users
of diclofenac (1.4 episodes per person).
Dispensing of nepafenac increased dur-
ing the study period, while dispensing
of ketorolac and diclofenac was
approximately stable, with a mild
increase towards the end of the study
period (Fig. 2). Of nepafenac users,
58% were women; 12% had diabetes
and 23% used antithrombotic agents
(Table 1). The demographics, health
characteristics and dispensing of oph-
thalmic and systemic drugs in users of
ketorolac and diclofenac were similar
to those in nepafenac users, although
users of ketorolac and diclofenac
seemed to be somewhat younger and
had lower Charlson comorbidity scores
(Table 1).
Age
The mean age of nepafenac users at
cohort entry was 72 years. Of 73 648
nepafenac therapy episodes, 237 epi-
sodes (0.3%) were in persons aged
18 years or younger (Table 1). Few
episodes of ketorolac or diclofenac
dispensing occurred in children, 3%
for ketorolac and 4% for diclofenac in
Denmark.
Cataract surgery, cataract diagnosis, other
diagnoses
Of the 73 411 nepafenac-use episodes
in adults, 41% had cataract surgery
(Table 2). Less than 1% each had
refractive procedures or ophthalmic
conditions within 30 days before and
30 days after the start date of the
therapy episode (Table 2). For both
ketorolac and diclofenac, dispensing
associated with cataract surgery in
adults was lower: 11% of ketorolac
episodes and 10% of diclofenac epi-
sodes. Using an expanded list of oph-
thalmic conditions that might have
triggered the dispensing of ophthalmic
NSAIDs, 12% of nepafenac-, 12% of
ketorolac- and 43% of diclofenac-use
episodes in patients with no cataract
surgery were associated with these
conditions (Table 5). Among patients
more likely to have better capture of
cataract surgery, those aged 80 years
or older and those with high comor-
bidity (Charlson comorbidity index
score of 3 or more), 44% of nepafenac
episodes were associated with cataract
surgery (Table 2).
Number of bottles
Of 73 411 nepafenac-use episodes in
adults, 4% involved 3-ml bottles and
96% of episodes involved 5-ml bottles
(Table 3). Approximately 92% of the
26 649 nepafenac episodes in patients
with cataract surgery and without dia-
betes involved one bottle; 99.8% of the
Table 3. Number of bottles per therapy episode for ophthalmic nepafenac, ketorolac and diclofenac in adults, the Netherlands (2008–2013) and
Denmark (1994–2014)
the Netherlands Denmark
Recorded cataract
surgery No cataract surgery Recorded cataract surgery No cataract surgery
Diabetes
n (%)
No diabetes
n (%)
Diabetes
n (%)
No diabetes
n (%)
Diabetes
n (%)
No diabetes
n (%)
Diabetes
n (%)
No diabetes
n (%)
Nepafenac
Number of episodes 441 2266 1735 8215 3801 26 649 4872 38 089
Number of bottles (3 ml)*
1 – – – – 139 (98) 1023 (98) 222 (98) 1589 (95)
2 – – – – 3 (2) 16 (2) 5 (2) 78 (5)
>2 – – – – 0 (0) (n < 3) 0 (0) (n < 3)
Number of bottles (5 ml)
1 260 (59) 1360 (60) 1212 (70) 6086 (74) 3319 (91) 23 416 (91) 4173 (90) 32 534 (89)
2 135 (31) 669 (30) 288 (17) 1271 (15) 328 (9) 2088 (8) 429 (9) 3601 (10)
>2 46 (10) 237 (10) 235 (14) 857 (10) 9 (0.2) 91 (0.4) 35 (0.8) 225 (0.6)
Drug supply duration
≤21 days 1 (0.2) 44 (2) 84 (5) 543 (7) 0 (0) 0 (0) 0 (0) 0 (0)
>21–60 days 252 (57) 1363 (60) 1240 (71) 5924 (72) 1967 (52) 13 856 (52) 2733 (56) 23 106 (60)
>60 days 188 (43) 859 (38) 411 (24) 1748 (21) 1834 (48) 12 793 (48) 2139 (44) 14 983 (39)
Ketorolac
Number of episodes 222 1215 968 5103 1385 9566 5479 83 054
Duration
≤21 days 2 (1) 6 (0.5) 30 (3) 203 (4) 0 (0) 0 (0) 0 (0) 0 (0)
>21–60 days 162 (73) 888 (73) 681 (70) 3653 (72) 648 (47) 4845 (51) 4077 (74) 65 989 (77)
>60 days 58 (26) 321 (26) 257 (27) 1247 (24) 737 (53) 4721 (49) 1402 (26) 17 065 (20)
Diclofenac
Number of episodes 182 734 889 4110 1707 16 178 8326 151 543
Duration
≤21 days 0 (0) 2 (0.3) 20 (2) 168 (4) 192 (11) 2271 (14) 3126 (37) 79 663 (50)
>21–60 days 109 (60) 525 (72) 328 (37) 1584 (39) 992 (58) 9318 (56) 4129 (49) 62 187 (39)
>60 days 73 (40) 207 (28) 541 (61) 2358 (57) 523 (31) 4589 (28) 1071 (13) 9693 (6)
* In the Netherlands, 3-ml bottles were used in only two episodes. For 86 episodes in Denmark, the size of the bottle was not recorded as 3 or 5 ml.
513
Acta Ophthalmologica 2017
3801 episodes in patients with cataract
surgery and diabetes involved up to
two bottles. Of 7684 therapy episodes
with recorded cataract surgery in
adults when only the ﬁrst indication
had been approved, 81% were for one
bottle (Table S1). Later, when both
indications had been approved, 96% of
19 980 therapy episodes in adults with
recorded cataract surgery were for the
approved durations. The duration of
ketorolac use in patients with cataract
surgery was similar to that of nepafe-
nac. In patients not undergoing catar-
act surgery, there was a tendency
towards shorter treatments with
ketorolac. Use of diclofenac in all
patient groups tended to be shorter
than use of nepafenac.
Table 4. Concomitant medication use by recorded cataract surgery and diabetes for ophthalmic nepafenac, ketorolac and diclofenac therapy
episodes, the Netherlands (2008–2013) and Denmark (1994–2014)
Variables
the Netherlands Denmark
Recorded cataract
surgery No cataract surgery
Recorded cataract
surgery No cataract surgery
Diabetes
n (%)
No diabetes
n (%)
Diabetes
n (%)
No diabetes
n (%)
Diabetes
n (%)
No diabetes
n (%)
Diabetes
n (%)
No diabetes
n (%)
Nepafenac
Number of episodes 441 2268 1735 8247 3801 26 659 4874 38 314
Ophthalmic medications
Other NSAIDs* 44 (10) 196 (9) 24 (1) 133 (2) 33 (0.9) 194 (0.7) 50 (1) 513 (1)
Steroids 395 (90) 2025 (89) 1032 (59) 4837 (59) 2729 (72) 19 221 (72) 3282 (67) 25 517 (67)
Prostaglandin analogues 9 (2) 50 (2) 30 (2) 223 (3) 162 (4) 1258 (5) 203 (4) 1801 (5)
Other ophthalmic medications 113 (26) 598 (26) 774 (45) 3597 (44) 439 (12) 3448 (13) 778 (16) 7048 (18)
Systemic medications
Antithrombotic agents 155 (35) 532 (23) 592 (34) 1590 (19) 1591 (42) 6007 (23) 1980 (41) 7447 (19)
NSAIDs 24 (5) 148 (7) 94 (5) 520 (6) 277 (7) 1774 (7) 405 (8) 2517 (7)
Steroids 21 (5) 93 (4) 70 (4) 337 (4) 128 (3) 967 (4) 159 (3) 1389 (4)
Ketorolac
Number of episodes 222 1216 968 5134 1385 9573 5487 85 889
Ophthalmic medications
Other NSAIDs* 148 (67) 793 (65) 25 (3) 114 (2) 21 (2) 149 (2) 53 (1) 663 (0.8)
Steroids 209 (94) 1175 (97) 193 (20) 935 (18) 1324 (96) 8936 (93) 1347 (25) 15 938 (19)
Prostaglandin analogues 10 (5) 31 (3) 22 (2) 112 (2) 39 (3) 386 (4) 230 (4) 1949 (2)
Other ophthalmic medications 174 (78) 870 (72) 454 (47) 2637 (51) 123 (9) 1151 (12) 1280 (23) 23 151 (27)
Systemic medications
Antithrombotic agents 68 (31) 239 (20) 362 (37) 928 (18) 536 (39) 2030 (21) 1957 (36) 10 864 (13)
NSAIDs 13 (6) 79 (6) 57 (6) 310 (6) 96 (7) 641 (7) 682 (12) 8384 (10)
Steroids 12 (5) 47 (4) 37 (4) 170 (3) 51 (4) 343 (4) 233 (4) 3452 (4)
Diclofenac
Number of episodes 182 734 890 4144 1707 16 210 8351 158 093
Ophthalmic medications
Other NSAIDs* 1 (1) 12 (2) 37 (4) 142 (3) 20 (1) 155 (1) 67 (0.8) 840 (0.5)
Steroids 152 (84) 576 (78) 527 (59) 2202 (53) 899 (53) 8452 (52) 2097 (25) 37 402 (24)
Prostaglandin analogues 11 (6) 21 (3) 31 (3) 165 (4) 50 (3) 690 (4) 377 (5) 3177 (2)
Other ophthalmic medications 22 (12) 81 (11) 301 (34) 1565 (38) 286 (17) 2940 (18) 3676 (44) 82 373 (52)
Systemic medications
Antithrombotic agents 65 (36) 168 (23) 304 (34) 943 (23) 596 (35) 2936 (18) 2505 (30) 12 201 (8)
NSAIDs 8 (4) 32 (4) 58 (7) 358 (9) 157 (9) 1323 (8) 1034 (12) 14 289 (9)
Steroids 12 (7) 25 (3) 36 (4) 153 (4) 76 (4) 754 (5) 327 (4) 4510 (3)
NSAIDs = non-steroidal anti-inﬂammatory drugs.
* The category other NSAIDs reﬂects all other NSAIDs except the one being reported.
Fig. 2. Episodes of Use of Nepafenac, Ketorolac and Diclofenac, Denmark
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Concomitant use
Patterns of concomitant drug use var-
ied somewhat for the three drugs
(Table 4). Concomitant use of oph-
thalmic steroids was higher for patients
with cataract surgery, but the diﬀer-
ence was small in nepafenac users.
Discussion
This was a collaborative drug utiliza-
tion study in two European countries
to describe the use of nepafenac, with
9530 patients with one or more nepafe-
nac dispensings in the Netherlands and
60 403 in Denmark. We observed
increased nepafenac dispensing during
the study period in both populations.
Context is provided by similar analyses
for ophthalmic preparations of ketoro-
lac and diclofenac. Patterns of dispens-
ing of the three drugs were roughly
similar in the Netherlands, but not in
Denmark.
There are three main aspects related
to the indication for nepafenac: age
(nepafenac is indicated in adults), pres-
ence of cataract surgery (nepafenac is
indicated for use hrs before and several
weeks after cataract surgery) and dura-
tion of treatment (up to 21 days in
patients undergoing cataract surgery
and up to 60 days after cataract
surgery in patients with diabetes).
Regarding age, 99.7% of nepafenac
therapy episodes in the Netherlands
and Denmark occurred in patients
older than 18 years. Of the therapy
episodes in adults, 21% in the Nether-
lands and 41% in Denmark had codes
for cataract surgery. We believe this is
an underestimate due to incomplete
capture of cataract surgeries in the data
sources in both countries. In the
Netherlands, 60% of adult patients
with recorded cataract surgery and no
diabetes used one bottle per episode,
and 90% of adult patients with
recorded cataract surgery and diabetes
used up to two bottles. In Denmark,
duration of use was within the autho-
rized limits for 92% of adult patients
with recorded cataract surgery and no
diabetes and for 99.8% of those with
cataract surgery and diabetes. Using
maximum days’ supply would likely
overestimate unapproved product use
(i.e. oﬀ-label use); however, using the
number of bottles is potentially under-
estimating unapproved product use.
Since the initial development of
nepafenac for ophthalmic use, there
have been concerns that it may be
prescribed for use beyond the approved
indications. Indeed, through the years,
reports that describe or recommend the
use of nepafenac for a number of
ophthalmic conditions and procedures
have been published (Wilson et al.
2015): maintenance of mydriasis during
ophthalmic surgery (Cervantes-Coste
et al. 2009; Zanetti et al. 2012; Sarkar
et al. 2015; Rodrigues et al. 2016) and
treatment for diabetic macular oedema
(Callanan & Williams 2008), cystoid
macular oedema (Warren & Fox 2008),
pain after photorefractive keratectomy
(Caldwell & Reilly 2008; Faktorovich
& Melwani 2014; ), recalcitrant macu-
lar degeneration (Chen et al. 2010;
Libondi & Jonas 2010), macular
oedema after epiretinal surgery
(Schoenberger et al. 2011), pain and
inﬂammation after vitreoretinal sur-
gery (Naithani et al. 2012), acute cen-
tral chorioretinopathy (Alkin et al.
2013), postoperative inﬂammation
after small-gauge vitrectomy (Nagpal
et al. 2014), ocular discomfort after
vitreous injections (Ulrich 2014) and
postoperative pain associated with
pterygium surgery (Ozcimen et al.
2015). However, we did not ﬁnd pub-
lished studies describing the frequency
of nepafenac use or dispensing for the
approved indication or other condi-
tions in routine health care, as we did
in this study.
The main limitation of this study is
the incompleteness of capture of catar-
act surgeries and other ophthalmic
conditions in the data sources. In the
Netherlands, the Hospitalisation Data-
base in PHARMO would miss ambu-
latory procedures. As many of the
ophthalmic procedures in this study
are performed during outpatient visits,
the number of ophthalmic procedures
is likely to be underestimated. In Den-
mark, cataract surgeries conducted in
public hospitals are recorded in the
Danish National Patient Registry (Sch-
midt et al. 2015). In 2002, to shorten
the wait for this surgery, cataract
surgeries started being oﬀered by pri-
vate hospitals or clinics at government
expense (Solborg Bjerrum et al. 2013).
Reporting these surgeries to the Danish
National Patient Registry has been
voluntary since 2002 and mandatory
since 2004 or 2006 (Solborg Bjerrum
et al. 2013, 2015). However, during the
course of this study, evidence surfaced
that some surgeries occurring in the
private setting were not systematically
recorded in the Danish National
Patient Registry. In a study of infec-
tious endophthalmitis, a dreaded but
rare complication of cataract surgery,
the authors found that only 59% of
those cases that by manual chart review
were found to be related to cataract
surgery had a record of surgery in the
registry. It could be estimated that 98%
of surgeries performed in hospitals
were recorded, while this proportion
was 38% for private clinics (Solborg
Bjerrum et al. 2013). Older patients
and patients with a high level of
comorbidity were more likely to have
their surgery performed in a hospital.
Thus, sensitivity analyses were
designed and implemented in both data
sources to address this underrecording.
Table 5. Ophthalmologic conditions related to potential oﬀ-label use of nepafenac, ketorolac and
diclofenac, Denmark, 1994–2014
Nepafenac episodes
(n = 73 648)
Ketorolac episodes
(n = 102 334)
Diclofenac episodes
(n = 184 361)
No cataract surgery 43 188 (59) 91 376 (89) 166 444 (90)
Cataract 2701 (6) 908 (1) 2550 (2)
Keratitis 143 (0.3) 305 (0.3) 2890 (2)
Conjunctivitis 2470 (6) 9284 (10) 64 454 (39)
Foreign body 63 (0.1) 166 (0.2) 4059 (2)
Ocular trauma 113 (0.3) 191 (0.2) 7693 (5)
Hordeolum (n < 3) 7 (<0.1) 37 (<0.1)
Chalazion 3 (<0.1) (n < 3) 10 (<0.1)
Blepharitis 8 (<0.1) 12 (<0.1) 42 (<0.1)
Welder’s eye 24 (0.1) 32 (<0.1) 515 (0.3)
Traumatic corneal lesion 90 (0.2) 147 (0.2) 7147 (4)
Acute allergic conjunctivitis 7 (<0.1) 36 (<0.1) 99 (0.1)
Cystoid macular oedema 62 (0.1) 97 (0.1) 123 (0.1)
Any of the above 5235 (12) 10 573 (12) 70 814 (43)
These are results from a sensitivity analysis implemented in Denmark. Results from similar
analyses in the Netherlands are presented in Table 3.
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In the Netherlands, we observed that
57% of nepafenac episodes had an
ophthalmic procedure, condition or
correspondence within 1 month before
or after the start of the episode. In
Denmark, we found a larger percent-
age of therapy episodes with recorded
cataracts in sicker and older patients
than in the study population, providing
evidence of underrecording of cataract
surgery in younger and healthier
patients (with less underrecording for
nepafenac than for ketorolac or
diclofenac) or more use of the drugs
unrelated to cataract surgery in
younger and healthier patients. In the
Netherlands, a national cataract reg-
istry exists. This registry, maintained
by the ophthalmic society Nederlands
Oogheelkundig Gezelschap, does not
include detailed information on medi-
cation use and would therefore not be
suitable for our study. We considered
linking the PHARMO Database Net-
work and the cataract registry. How-
ever, in 2011, only 50% of cataract
surgeries were entered into this registry;
linkage to this cataract registry would
not have solved the limitation.
Another limitation is that we did not
have information on whether prescrip-
tions were written to cover treatment
for one or two eyes. However, based on
the observation that 86% of patients in
the Netherlands had surgery in only
one eye and that cataract surgeries in
fellow eyes are separated by a few
weeks in Denmark (Solborg Bjerrum
et al. 2015), we assumed that therapy
episodes were for a single eye.
In conclusion, based on this evalua-
tion of 12 691 nepafenac therapy epi-
sodes in the Netherlands and 73 648 in
Denmark, we can conﬁrm that practi-
cally all dispensing of nepafenac is in
adults. In both populations, less than
half of the therapy episodes occurred in
patients with recorded cataract sur-
gery; however, substantial under-
recording of cataract surgery occurs
in Denmark and is likely in the Nether-
lands. For this reason, our observed
ﬁgures should be seen as the upper
limit of the true number. Based on the
dispensed number of bottles, the esti-
mated duration of treatment is appro-
priate for the approved indication in
60% of adult patients without diabetes
and 90% of adult patients with dia-
betes in the Netherlands, and in 92%
and 99.8%, respectively, in Denmark.
The underrecording of ophthalmic
conditions in automated healthcare
databases used in pharmacoepidemiol-
ogy is higher than initially expected
and challenges research in this impor-
tant indication.
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